Tamami Ukaji Selected Research

epoxyquinomicin A

3/2018

Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tamami Ukaji Research Topics

Disease

5	Neoplasms (Cancer) 01/2019 - 09/2014
4	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2015
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Inflammation (Inflammations) 12/2018
1	Leukemia 12/2018
1	Carcinoma (Carcinomatosis) 01/2015

Drug/Important Bio-Agent (IBA)

1	ketomycinIBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	titanium dioxide (Titania)FDA Link 12/2018
1	phorbolIBA 12/2018
1	InterleukinsIBA 12/2018
1	epoxyquinomicin AIBA 03/2018
1	Interleukin-8 (Interleukin 8)IBA 03/2018
1	dehydroxymethylepoxyquinomicinIBA 01/2017
1	Matrix Metalloproteinases (MMPs)IBA 01/2017
1	migracin AIBA 01/2015
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2015

Therapy/Procedure

1	Therapeutics 09/2014
1	Drug Therapy (Chemotherapy) 09/2014
1	Radiotherapy 09/2014